Altre lingue BiVictriX Therapeutics Plc

Azioni

BVX

GB00BNXH3K91

Mercato chiuso - London S.E. Altri mercati azionari 17:35:24 01/05/2024			Variaz. 5gg	Var. 1 gen.
11,5 ^GBX	0,00%		0,00%	+9,52%

17/04	Bivictrix ottiene lo status di farmaco orfano dalla FDA per il trattamento di un tumore raro	AN
2023	Bivictrix Therapeutics plc annuncia le dimissioni di Iain Ross dal Consiglio di Amministrazione	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Bivictrix granted FDA orphan drug status for rare cancer treatment	17/04
BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment	17/04
Bivictrix Therapeutics plc Announces Resignation of Iain Ross from the Board	05/12
Bivictrix selects final sequences for lead tumour programme	30/11
BiVictriX Therapeutics plc Announces Pipeline Update on Lead Solid Tumour Programme, Bvx002	30/11
BiVictriX patent boost; 4Global deal extended	15/11
BiVictriX Obtains Japanese Patent for Acute Myeloid Leukemia Drug Conjugate	15/11
Bivictrix Therapeutics Says Patent Granted In Japan Providing Further Broad Protection For BVX001	15/11
Bivictrix says BVX001 increases survival rates by more than double	12/10/23
BiVictriX Therapeutics' Blood Cancer Drug Delivers Extended Survival Rates in Trial	12/10/23
Bivictrix Therapeutics PLC Extended Survival Rates Reported With Bvx001 In A Pre-Clinical Model Of Acute Myeloid Leukaemia	12/10/23
BiVictriX Therapeutics appoints combined CFO/CBO to boost out-licensing efforts	06/10/23
Bivictrix hires new CFO as Alex Hughes steps down after seven months	03/10/23
BiVictriX Therapeutics Appoints New CFO, Chief Business Officer	03/10/23
BiVictriX Therapeutics Plc Announces Chief Financial Officer Changes	03/10/23
BiVictriX Therapeutics Plc Appoints Adrian Howd as Chief Business Officer	03/10/23
BiVictriX Therapeutics "looking really healthy" after positive first half	20/09/23
AEW UK REIT appoints new chair; Oberon raises money	19/09/23
Earnings Flash (BVX.L) BIVICTRIX THERAPEUTICS Posts H1 Loss GBX-1.77	19/09/23
BiVictriX Therapeutics Plc Reports Earnings Results for the Half Year Ended June 30, 2023	19/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue BiVictriX Therapeutics Plc

Azioni

BVX

GB00BNXH3K91

Altre lingue

Filtri